MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
复制标题
DOI：
10.1186/1746-1596-7-31
复制
发表时间：
2012-03-22
影响因子：
2.6
通讯作者：
Vyzula R
中科院分区：
文献类型：
--
作者：
Svoboda M;Sana J;Redova M;Navratil J;Palacova M;Fabian P;Slaby O;Vyzula R
乳腺癌是最常见的恶性肿瘤，在全世界妇女中发病率最高。三阴性乳腺癌（TNBC）代表了乳腺癌基底细胞样分子亚型的主要表型，其特征是年轻女性发病率较高，预后极差。MicroRNA（miRNAs）是一类小分子非编码RNA，在包括乳腺癌在内的多种癌症的发病机制中起重要作用。因此，miRNA也是三阴性乳腺癌患者中潜在的预后和/或预测生物标志物。39例具有可用福尔马林固定石蜡包埋（FFPE）组织的TNBC患者入组研究。使用qRT-PCR分析miR-34 a、miR-34 b和miR-34 c，并将其与TNBC患者的临床病理学特征相关联。miR-34 b的表达水平与TNBC患者的无病生存期（DFS）（p = 0.0020，对数秩检验）和总生存期（OS）（p = 0.0008，对数秩检验）显著相关。未观察到miR-34 a、miR-34 b和miR-34 c与可用临床病理学数据之间的其他显著关联。miR-34 b表达与TNBC患者的无病生存期和总生存期呈负相关。因此，miR-34 b可能是TNBC患者中一种新的有希望的预后生物标志物，但需要独立验证。
Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients. Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological features of TNBC patients. Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients. No other significant associations between miR-34a, miR-34b, and miR-34c with available clinical pathological data were observed. MiR-34b expression negatively correlates with disease free survival and overall survival in TNBC patients. Thus, miR-34b may present a new promising prognostic biomarker in TNBC patients, but independent validations are necessary.
登录
查看更多内容
影响因子：
50.5
作者：
Chu, D.;Zhang, Z.;Ji, G.
通讯作者：
Ji, G.
影响因子：
2.1
作者：
Juan, David;Alexe, Gabriela;Liou, Louis S.
通讯作者：
Liou, Louis S.
影响因子：
45.3
作者：
Voduc, K. David;Cheang, Maggie C. U.;Kennecke, Hagen
通讯作者：
Kennecke, Hagen
影响因子：
4.3
作者：
Yamakuchi, Munekazu;Lowenstein, Charles J.
通讯作者：
Lowenstein, Charles J.
影响因子：
64.8
作者：
He, Lin;He, Xingyue;Hannon, Gregory J.
通讯作者：
Hannon, Gregory J.